NeXstar regulatory update

NXTR's AmBisome liposomal formulation of amphotericin B received approval in Spain to treat life-threatening systemic fungal infections that fail to respond to amphotericin B therapy or when amphotericin B is contraindicated. AmBisome also was approved to treat visceral leishmaniasis infection in immune compromised and HIV-infected patients. Sales will begin immediately. ...